TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05834049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Parental Presence on Induction of Anesthesia
Description: Apple Inc's FaceTime™ video application will be used when the child is taken to the operating room

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Preoperative midazolam (0.5 mg/kg of oral midazolam with a maximum dose of 20mg) will be given unless medically contraindicated.
Study: NCT05398016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-intensity intervention for anxiety
Description: Brief (4-6 weekly 30-min sessions) delivery of a structured behavioral treatment for mild-to-moderate anxiety. Treatment will be based on principles of cognitive behavioral therapy (CBT).
Study: NCT05956847

Intervention type: PROCEDURE
Intervention: gastroscopy
Description: When performing gastroscopy, the endoscopist will perform a biopsy based on the condition of gastric mucosal lesions, with one specimen retained and the remaining specimens subjected to pathological examination
Study: NCT06320704

Intervention type: DEVICE
Intervention: Digital occlusal adjustment using Occulosense digital device
Description: Digital occlusal adjustment of mandibular complete denture using Occulosense digital device
Study: NCT05444738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral lollipop with oxytocin (24IU)
Description: Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral lollipop with placebo
Description: Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
Study: NCT05531552

Intervention type: DRUG
Intervention: clinical pharmacy application
Description: assessment clinical pharmacist in management of CAD and ICU patients.
Study: NCT05631262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: Subjects of Cohot 1-5 and Part II Test group will receive SKB264 monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Part II Control group will receive docetaxel monotherapy.
Study: NCT05573698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-216
Description: DT-216 will be administered by intravenous (IV) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered by intravenous (IV) injection
Study: NCT06095141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2, ivgtt, 30 min, D1, 8. The administration of other chemotherapeutic agents including gemcitabine, nab-paclitaxel, fluorouracil, irinotecan, capecitabine is applied according to the National Comprehensive Cancer Network (NCCN) guideline. PARP inhibitor will be recommended to patients with platinum-sensitive metastatic PDAC after six months of cisplatin based regimen.
Study: NCT04874532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Paramedic Program
Description: Patients will be seen for a 1-hr in person evaluation and follow-up will be determined on an individual basis based on patient need. During each visit, CPs will perform health status and social determinants of health assessments, physical exam, medication review/counseling, and goal setting/review.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Material
Description: Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Material
Description: Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
Study: NCT04768166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat 100 MG
Description: 100mg/TID in 4w then 200mg/TID in 8 w
Study: NCT05317013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: CBD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05867199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery and Action Observation Training
Description: The training consists of watching videos of actions performed with the hand. At the end of the video the subject is subsequently asked to imagine performing the action just seen
Study: NCT06118645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab combined +paclitaxel (albumin-bound)
Description: 1. In the safe induction phase6 subjects will receive cadonilimab (10mg/kg, Q3W, intravenous infusion, up to 2 years) and paclitaxel (albumin-bound type)(125 mg/m2,Days1, 8,Q3w, intravenous infusion, up to 8 cycles).~2. If the safety and tolerability are good, and the initial efficacy signal is observed, the extended enrollment phase will enter the extended enrollment phase of drug administration and the safety introduction phase
Study: NCT05335252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: 5mg 2x daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 caplet 2x daily for 7 days
Study: NCT06459596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communal Coping Intervention
Description: The components of the intervention were described in the experimental arm.
Study: NCT05113199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Dignity Therapy
Description: Virtual Dignity Therapy will be facilitated by a registered nurse or medical doctor trained in Dignity Therapy.
Study: NCT06395116

Intervention type: OTHER
Intervention: Denture base material
Description: Denture base material constructed with different techniques for completely edentulous populations

Intervention type: OTHER
Intervention: Denture base material
Description: Denture base material constructed with different techniques for completely edentulous populations

Intervention type: OTHER
Intervention: Denture base material
Description: Denture base material constructed with different techniques for completely edentulous populations
Study: NCT04597294

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FLOT + HIPEC + Surgery
Description: HIPEC with irinotecan after 4 doses of preoperative FLOT chemotherapy
Study: NCT05704153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym 1Hz
Description: Transcutaneous auricular vagus nerve stimulation of 1Hz

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym 30Hz
Description: Transcutaneous Auricular Vagus Nerve Stimulation of 30Hz
Study: NCT04689841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vojta Therapy
Description: Reflex locomotion is activated by the reflexogenic pathway. In context with reflex locomotion, the term reflex does not represent the mode of neuronal control, but rather refers to defined, automatic and always equal motor responses produced by external stimuli, applied therapeutically.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In the control group, a placebo intervention is administered, similar to an experimental intervention
Study: NCT05704153

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Sham stimulation
Study: NCT04941690

Intervention type: OTHER
Intervention: A questionnaire method was used.
Description: The questionnaire included general population information, International Index of Sexual Function-5 (IIEF-5), Premature Ejaculation Diagnostic Tool (PEDT), General Anxiety Disorder-7 and CPSI.

Intervention type: OTHER
Intervention: A questionnaire method was used.
Description: The questionnaire included general population information, International Index of Sexual Function-5 (IIEF-5), Premature Ejaculation Diagnostic Tool (PEDT), General Anxiety Disorder-7 and CPSI.

Intervention type: OTHER
Intervention: A questionnaire method was used.
Description: The questionnaire included general population information, International Index of Sexual Function-5 (IIEF-5), Premature Ejaculation Diagnostic Tool (PEDT), General Anxiety Disorder-7 and CPSI.
Study: NCT05831345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Hydrochloride
Description: Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil Citrate
Description: Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
Study: NCT05568927

Intervention type: OTHER
Intervention: SEARCH algorithm
Description: The SEARCH algorithm is a structured, stepwise approach to follow up testing after acute PE that will enable timely diagnosis of post PE sequelae. The test results at each step inform the performance of the subsequent steps. The order of the tests in the algorithm uses the acronym SEARCH: Symptom screen, exercise function, arterial perfusion, resting heart function, confirmatory imaging, and hemodynamics.
Study: NCT04713579

Intervention type: OTHER
Intervention: No intervention - observational study
Description: There is no intervention in this study as it is purely observational.

Intervention type: OTHER
Intervention: No intervention - observational study
Description: There is no intervention in this study as it is purely observational.
Study: NCT05279105

Intervention type: BEHAVIORAL
Intervention: Program support
Description: The intervention to be evaluated in this study is program design and selection considerations by humanitarian organisations. It will comprise of factors that motivate organisations to chose certain delivery models in providing health care in conflict-affected settings

Intervention type: BEHAVIORAL
Intervention: Program support
Description: The intervention to be evaluated in this study is program design and selection considerations by humanitarian organisations. It will comprise of factors that motivate organisations to chose certain delivery models in providing health care in conflict-affected settings
Study: NCT06327620

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Daivobet ointment, topical steroids
Description: Daivobet Ointment: This intervention involves the topical application of Daivobet ointment, which is a combination of calcipotriol and betamethasone. The application is to be done three times daily for four weeks.~Topical Steroid: This intervention entails the topical application of a steroid ointment three times daily for four weeks. The specific steroid and its details are not disclosed in the provided information.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet ointment, topical steroids
Description: Daivobet Ointment: This intervention involves the topical application of Daivobet ointment, which is a combination of calcipotriol and betamethasone. The application is to be done three times daily for four weeks.~Topical Steroid: This intervention entails the topical application of a steroid ointment three times daily for four weeks. The specific steroid and its details are not disclosed in the provided information.
Study: NCT04969341

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT04914117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC118 for injection
Description: RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
Study: NCT04597294

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FLOT + Surgery
Description: Perioperative FLOT chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery
Study: NCT05341297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentKIT
Description: The intervention is structured in 9 modules through which parents learn to identify and manage their children's anxiety and depressive symptoms. The Internet intervention is guided by two psychotherapists under supervision training in Cognitive Behavioral Therapy, trained by the first author on the treatment protocol.
Study: NCT04724044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tablets
Description: Oral tablets of similar appearance to active study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Oral tablets of 500mg of clarithromycin
Study: NCT05805735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face care product (Eye cream)
Description: The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects
Study: NCT06406946

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lion's mane blend
Description: 1.8 gram per day of lions mane, consisting of 3 x 600mg capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lion's mane and reishi blend
Description: 1.8 gram per day of lions mane and reishi blend, consisting of 3 x 600mg capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.8-gram microcrystalline cellulose placebo powder, 3x600mg capsules
Study: NCT05387538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-layer Duct-to-mucosa Pancreaticojejunostomy
Description: To create the anterior suturing layers, double needles with a 4/0 or 3/0 Prolene line will be used; one side of the needles will be inserted from the anterior inner side of the pancreatic duct and out through the ventral parenchyma of the pancreatic stump to the anterior surface of the pancreas about 3 cm from the cut edge. The other side of the needles will be started from the inner side of the jejunum lumen, then pushed through the subserosa and seromuscular region, and out from the posterior surface of the bowel but its done after completion of the posterior layer. The posterior suturing layer will be treated in the same manner. An internal pancreatic duct stent will be used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-layer Duct-to-mucosa Pancreaticojejunostomy
Description: The same double needle and 4/0 or 3/0Prolene line will be used. First, the region approximately 1.0 cm from the cutting edge of the pancreatic remnant will be freed; then, the posterior surface of the pancreatic remnant will be sutured to the seromuscular layer of the jejunum using the interrupted suturing method. The jejunum will be brought closer to the stump of the pancreas, and a hole of similar diameter to the main pancreatic duct will be made on the jejunum near the entrance of the main pancreatic duct. The posterior wall of the jejunum near the hole will be sutured to the posterior wall of the pancreatic duct using the interrupted suturing method with Prolene line, and a suitable internal pancreatic duct stent will used . The interior side of the jejunum and pancreas will be sutured using the same method. Then, the anterior surface of the pancreatic remnant and the seromuscular layer of the jejunum will be tightly sutured using the interrupted method.
Study: NCT00761488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® Toric IOL
Description: Implanted into the study eye
Study: NCT05577026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention and prescription feedback
Description: Brief educational intervention and patient and provider materials regarding prescription of opioids. Subsequent feedback on clinic prescription of opioids over 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General information on treatment guidelines
Description: Written information on guidelines and recommendations regarding prescription of opioids.
Study: NCT06005909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne-Cooksey Exercises
Description: A- Head and Eye Movements While Lying and Sitting:~1. While keeping your head still, look up and then down again.~2. Look from side to side while keeping your head still.~3. Extend your hand at arm's length, draw your fingers towards your nose while focusing your eyes on your fingers.~4. With eyes open, slowly turn your head from side to side.~5. Turn your head from side to side quickly.~6. With eyes open, slowly move your head up and down.~7. Move your head up and down quickly.~8. Repeat items 4,5,6 and 7 with your eyes closed.~B-Head and Body Movements While Sitting:~1. Place an object on the floor in front of your feet, reach out to pick it up, then upright return to your position. Looking down while picking up the item, then Remind you to look up when trying to fix it.~2. Lean forward and move the object forward and back under your knees. C- Standing Exercises~1-Get from a sitting position to a standing position and sit down again. 2-Repeat this with your eyes closed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Hippotherapy Exercises
Description: From the patient on the mechanical hippotherapy device;~* Maintaining trunk balance while raising both hands above head,~* Maintaining trunk balance while opening the arms next to the trunk,~* Maintaining trunk balance while extending the arms back and forth with successive movements,~* Maintaining trunk balance with hands clasped behind the waist,~* The arms are open to both sides, while transferring the weight ball from one hand to the other, it is requested to maintain the body balance.
Study: NCT06465784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde and Antegrade Ureteroscopic Laser Lithotripsy
Description: Comparison Between Retrograde and Antegrade Ureteroscopic Laser Lithotripsy for Management of Medium Sized Proximal Ureteral Stones: A Randomized Prospective Study

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde and Antegrade Ureteroscopic Laser Lithotripsy
Description: Comparison Between Retrograde and Antegrade Ureteroscopic Laser Lithotripsy for Management of Medium Sized Proximal Ureteral Stones: A Randomized Prospective Study
Study: NCT01237925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine 1% gel
Description: Small amount applied over the lesion twice a day for 7 days
Study: NCT04758598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Selective Laser Trabeculoplasty (DSLT)
Description: DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty (SLT)
Description: SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
Study: NCT04950205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalant product
Description: propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
Study: NCT05922995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20 mg capsules taken on a nightly basis
Study: NCT01237925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine 1% cream
Description: Small amount applied over the lesion twice a day for 7 days
Study: NCT05843812

Intervention type: DRUG
Intervention: Magnesium Sulfate 10 MG/ML
Description: Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management
Study: NCT05099536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D011-08
Description: participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).